Identification

Generic Name
Adrafinil
DrugBank Accession Number
DB08925
Background

Adrafinil is a mild central nervous system stimulating drug typically employed to relieve excessive sleepiness and inattention in geriatric patients. It is also been used off-label to prevent fatigue or falling asleep for extended periods of time. Adrafinil does not currently have FDA approval and is thus unregulated in the United States. It was marketed in France and elsewhere in Europe under the trade name Olmifon until September 2011 when France's FDA equivalent reassessed the drug and withdrew marketing permission. Adrafinil is metabolized to modafinil.

Type
Small Molecule
Groups
Withdrawn
Structure
Weight
Average: 289.35
Monoisotopic: 289.077264521
Chemical Formula
C15H15NO3S
Synonyms
  • Adrafinil
  • Adrafinilum
External IDs
  • CRL 40028
  • CRL-40028

Pharmacology

Indication

Used to relieve excessive sleepiness and inattention in elderly patients.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Adrafinil is a prodrug; it is primarily metabolized in vivo to modafinil, resulting in nearly identical pharmacological effects. Unlike modafinil, the active metabolite must accumulate before the drug is able to act. Oral adrafinil without food usually begins to act within 45 minutes to 1 hour.

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcebutololThe therapeutic efficacy of Adrafinil can be decreased when used in combination with Acebutolol.
AceclofenacThe risk or severity of hypertension can be increased when Aceclofenac is combined with Adrafinil.
AcemetacinThe risk or severity of hypertension can be increased when Adrafinil is combined with Acemetacin.
Acetylsalicylic acidThe risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Adrafinil.
AclidiniumThe risk or severity of Tachycardia can be increased when Aclidinium is combined with Adrafinil.
AdenosineThe risk or severity of Tachycardia can be increased when Adenosine is combined with Adrafinil.
AlclofenacThe risk or severity of hypertension can be increased when Adrafinil is combined with Alclofenac.
AlfentanilThe risk or severity of hypertension can be increased when Alfentanil is combined with Adrafinil.
AlfuzosinThe therapeutic efficacy of Adrafinil can be decreased when used in combination with Alfuzosin.
AliskirenAdrafinil may decrease the antihypertensive activities of Aliskiren.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Active Moieties
NameKindUNIICASInChI Key
ModafinilprodrugR3UK8X3U3D68693-11-8YFGHCGITMMYXAQ-UHFFFAOYSA-N
International/Other Brands
Olmifon (Cephalon)

Categories

ATC Codes
N06BX17 — Adrafinil
Drug Categories
Classification
Not classified
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
BI81Z4542G
CAS number
63547-13-7
InChI Key
CGNMLOKEMNBUAI-UHFFFAOYSA-N
InChI
InChI=1S/C15H15NO3S/c17-14(16-18)11-20(19)15(12-7-3-1-4-8-12)13-9-5-2-6-10-13/h1-10,15,18H,11H2,(H,16,17)
IUPAC Name
2-diphenylmethanesulfinyl-N-hydroxyacetamide
SMILES
ONC(=O)CS(=O)C(C1=CC=CC=C1)C1=CC=CC=C1

References

General References
Not Available
KEGG Drug
D07348
PubChem Substance
347910387
ChemSpider
2297976
RxNav
45938
ChEBI
135200
ChEMBL
CHEMBL93077
Wikipedia
Adrafinil

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.758 mg/mLALOGPS
logP2.19ALOGPS
logP1.53Chemaxon
logS-2.6ALOGPS
pKa (Strongest Acidic)8.1Chemaxon
pKa (Strongest Basic)-5.5Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count3Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area66.4 Å2Chemaxon
Rotatable Bond Count5Chemaxon
Refractivity79.15 m3·mol-1Chemaxon
Polarizability29.63 Å3Chemaxon
Number of Rings2Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created at October 08, 2013 20:30 / Updated at May 14, 2021 01:05